Sunstone Life Science Ventures

A European early-stage venture capital firm founded in 2007, Sunstone Life Science Ventures invests in novel pharmaceutical ingredients for human therapeutic use. With a focus on the life science sector, they manage multiple funds totaling over €570M, investing across Northern and Western Europe.

Claus Andersson Ph.D

General Partner

Felix Becker

Analyst

Levin Bunz

Partner

Robert Cobuzzi Ph.D

Venture Partner

Yacine Ghalim

Partner

Angelo Panumaht Goepel

Analyst

Lærke Hansen

Principal

Christian Jepsen

Partner

Paulina Koschitz

Investor

Søren Lemonius

Co-Founder and Managing General Partner

Tobias Meisner

Principal

Jacob Moresco Ph.D

Investment Director

Maximilian Niederhofer

Partner

Max Niederhofer

Partner

Jimmy Fussing Nielsen

Partner

Björn Nilsen

Analyst

Yohan Pereira

Principal

Signe Marie Sveinbjørnsson

Partner

Sten Verland Ph.D

Co-Founder Founder and Venture Partner

Kenza Zayani

Analyst

Past deals in Copenhagen

Templafy

Series B in 2018
Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Grandhood

Seed Round in 2018
Grandhood is a Danish investment management firm established in 2016, headquartered in Copenhagen. The company specializes in retirement planning and pension services, aiming to modernize the traditionally stagnant workplace pension industry through digital innovation. Grandhood offers an online platform that enables employers to provide pensions to their employees, along with voluntary health insurance and other benefits. The platform facilitates digital onboarding and provides advisory services at a competitive cost, ensuring swift customer support. Grandhood continually updates its product to adapt to evolving consumer needs, targeting companies embracing digital solutions for workplace pension management.

Orphazyme

Post in 2017
Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Orphazyme

Venture Round in 2017
Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Templafy

Venture Round in 2015
Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Orphazyme

Series B in 2015
Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Issuu

Series B in 2014
Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.

Templafy

Venture Round in 2014
Templafy ApS, established in 2013, specializes in template and document management solutions. Its core product, the Templafy platform, connects and manages an organization's entire document ecosystem. Key features include template and content accessibility, dynamic personalization, document automation, brand and content validation, template governance, and PowerPoint productivity services. Templafy serves a wide range of industries, including banking, consulting, education, insurance, and legal, with a global presence across North America, Europe, Asia, and Australia. The company's innovative platform automates business document creation, ensuring brand compliance, governance, and improved productivity. It supports over 800 enterprise customers worldwide, such as KPMG and IKEA, and has raised $200 million in funding from prominent investors.

Mofibo

Seed Round in 2013
Mofibo, founded in Copenhagen in 2013, is one of the pioneering book subscription services globally. The company provides e-books through a proprietary platform that operates on a monthly subscription model, allowing consumers to access a diverse range of titles. Currently active in three countries, Mofibo plans to expand its reach into additional markets within the next year. With a focus on transforming the reading experience, Mofibo employs a data-driven and customer-centric approach to enhance how millions of people interact with books.

Nuevolution

Venture Round in 2012
Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.

Adenium Biotech

Venture Round in 2012
Adenium Biotech ApS is a Copenhagen-based biopharmaceutical company founded in 2011, specializing in the development and commercialization of novel antibiotics aimed at treating multi-drug resistant bacterial infections. The company focuses on addressing hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Its lead product, Arenicin, is a 21-amino acid antimicrobial peptide derived from the lugworm, demonstrating strong efficacy against Gram-negative pathogens while maintaining a broad therapeutic window. Adenium Biotech operates as a semi-virtual company, relying on a small team of experts supported by an international scientific advisory board to advance its clinical development programs toward regulatory approval.

Orphazyme

Series A in 2011
Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Orphazyme

Seed Round in 2011
Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Podio

Series A in 2011
Podio, a collaborative work platform now part of Citrix, is designed to enhance how teams manage their daily tasks and workflows. It empowers users to create customized workspaces that can be accessed in real-time by team members, integrating various functionalities such as messaging, task management, reporting, and contact management. By offering a wide range of specialized and flexible work applications, Podio streamlines processes and reduces the need for multiple disjointed tools, all while providing a single, organized environment for users. Trusted by thousands of teams and organizations globally, Podio facilitates efficient work processes and connects various work activities within a cohesive platform. Based in Copenhagen, the company has a diverse team comprising employees from Germany, France, Britain, and Denmark, led by CEO Tommy Ahlers.

Biomonitor

Venture Round in 2008
Biomonitor, founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen, specializes in providing biopharmaceutical development services to pharmaceutical and biotechnology companies. The company's foundation is rooted in Professor Klaus Bendtzen's extensive research on inflammation and immunology at the Copenhagen University Hospital. Biomonitor offers advanced biotechnology tools and methods to assist developers in designing and clinically evaluating their drug candidates, with a particular focus on monitoring biopharmaceuticals to ensure effective treatment outcomes for patients.

Issuu

Series A in 2007
Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.